Rocket Pharmaceuticals Announces Third Quarter 2026 Financial Results and Reports Key Business and Clinical Progress

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress Across Its Cardiovascular Gene Therapy Pipeline Rocket Pharmaceuticals, Inc., a fully integrated, commercial-stage biotechnology company focused on developing genetic…

Read MoreRocket Pharmaceuticals Announces Third Quarter 2026 Financial Results and Reports Key Business and Clinical Progress

Palleon Pharmaceuticals Reports Phase 2 Results of HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026

Palleon Pharmaceuticals Reports Early Proof-of-Concept Results for HLX79/E-602 in Primary Membranous Nephropathy Palleon Pharmaceuticals, a clinical-stage biotechnology company developing innovative glycan-editing therapeutics for autoimmune diseases and cancer, has announced encouraging…

Read MorePalleon Pharmaceuticals Reports Phase 2 Results of HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026

Vision-Language AI Model Improves Radiology Detection and Workflow Efficiency in Study of More Than 237,000 Exams

Mosaic Clinical Technologies Reports AI Vision-Language Models Improve Radiology Detection by Up to 110% Across More Than 237,000 Imaging Exams Mosaic Clinical Technologies, Inc. has announced promising preliminary research findings…

Read MoreVision-Language AI Model Improves Radiology Detection and Workflow Efficiency in Study of More Than 237,000 Exams